Exosomes Hold Great Potential, But Buyer Beware – You might have read claims about the new wonder stuff called exosomes. While the potential for improving health and combating disease is exciting, the current landscape is a mix of scientific progress and unsubstantiated claims. I’ve covered the exosome story since 2010, and here’s a summary of the current situation. For more information, read my chapter on exosomes in Discovering the Nature of Longevity.
What are they?
Exosomes are tiny vesicles released by cells that measure less than 150 nanometers, which is tiny compared to most cells. Every cell releases thousands of these, with each one being a programmed package of proteins, amino acids, DNA, and RNA. Your body contains exponentially more exosomes than it does cells, although exosomes exist for a much shorter time and are not “living” in the traditional sense. There are as many types of exosomes as there are cell types, and they perform a mind-boggling variety of functions that range from immune response and healing to infection and triggering heart disease. In a nutshell, exosomes are the body’s courier service that delivers messages between cells, as well as labs-on-a-chip that put new combinations of proteins together while in transit between cells. This powerful combination makes exosomes major players in the body’s overall health.
The Promise of Exosomes
Exosomes have shown potential in regenerative medicine, cancer treatment, and diagnostics. They have one powerful trait: they can enter cells without triggering an unintended immune response. This lowers the risks of unwanted side effects. Their ability to carry and deliver nutraceuticals and drugs makes them attractive candidates for targeted therapies.
As of 2024, there were 388 clinical trials underway exploring exosome-based diagnostics and therapeutics. These trials cover a wide range of applications, including:
- Cardiovascular diseases
- Neurological disorders
- Cancer
- Autoimmune disorders
- Inflammatory conditions
One phase I clinical trial for Crohn’s disease-related perianal fistulas demonstrated promising results, with 3 out of 5 patients exhibiting good results after mesenchymal stem cell (MSC)-derived exosome injections.
Two exosome-based diagnostics have received Fast Track approval from the U.S. FDA, indicating the growing recognition of their medical potential. Exosomal biomarkers have been identified for various diseases, including cancer, allowing the development of non-invasive diagnostic tests.
Reality Check
Despite promising research, it’s crucial to know that exosome therapies are still in their infancy. The FDA has made it clear that there are currently no FDA-approved exosome products. As of 2024, no exosome therapeutics had received marketing approval, although the first products are anticipated by 2029. This means that any exosome therapies being offered outside of clinical trials are not regulated or proven safe and effective. The FDA has also issued a public safety notification regarding exosome products, warning that clinics offering these treatments outside of the FDA’s review process may be taking advantage of patients and flouting federal regulations. The agency emphasizes that exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products and are subject to approval requirements.
Unsubstantiated Claims
The excitement surrounding exosomes has led to a proliferation of unproven and potentially dangerous offerings. A study by the University of California, Irvine revealed that in 2022, 38 North American businesses used direct-to-consumer advertising to promote unproven stem cell interventions and exosome products as purported treatments and preventatives for COVID-19.
Challenges and Limitations
Several factors contribute to the gap between exosome research and clinical application:
- Standardization issues: There’s a lack of uniform protocols for exosome isolation, characterization, and application.
- Limited large-scale clinical trials: Most studies involve small sample sizes and short follow-up periods.
- Safety concerns: Long-term safety data is still limited.
- Regulatory hurdles: Exosome-based products have not yet received widespread regulatory approval.
Buyer Beware: Red Flags to Watch For
Consumers should be wary of businesses making the following claims:
- Promises of cures or guaranteed results for complex conditions
- Claims of FDA approval or endorsement
- Assertions that exosome therapies are risk-free or have no side effects
- Marketing of exosomes for a wide range of unrelated conditions
- Use of patient testimonials as primary evidence of efficacy
Here’s what you can do
Exosomes represent an exciting frontier for diagnostics and therapeutics. However, the current landscape is a mix of promising scientific advancements and unsubstantiated claims. As research progresses, it’s crucial for consumers to approach exosome therapies with caution and skepticism. Patients interested in exosome therapies can:
- Consult with licensed healthcare professionals
- Seek treatments only through approved clinical trials
- Be wary of clinics making extraordinary claims
- Report any adverse events related to exosome products to the FDA’s MedWatch Adverse Event Reporting program
If you’re a science geek, you can follow the research progress of exosomes through the Journal of Extracellular Vesicles, which is sponsored by the International Society for Extracellular Vesicles (ISEV).
Legitimate Research Continues
Despite the challenges and misrepresentations in the market, legitimate research into exosome therapies continues to progress. For example:
- A clinical trial using Exo-CD24, an engineered exosome displaying CD24 glycoprotein, showed promising results in treating COVID-19 patients with mid/high severity.
- Studies in dermatology have demonstrated the potential benefits of exosomes for skin rejuvenation and treating sensitive skin conditions.
As the field of exosome research matures, we can expect more rigorous clinical trials, standardized protocols, and, eventually, FDA-approved therapies. Until then, it’s essential to remain cautious and well-informed about the current state of exosome science and its clinical applications.
This story was written with assistance from Perplexity.ai
- References
- Data Bridge Market Research. (2023). Exosome Therapeutics Market Size, Share & Trends By 2030.
- The Business Research Company. (2024). Global Exosome Research Market Report 2024.
- Globe Newswire. (2024, December 3). Exosome Research Products Industry Research Report 2023-2030.
- Global Market Estimates. (2024). Global Exosomes Market Analysis | Size & Forecasts.
- MarkNtel Advisors. (2024). Exosomes Market Size & Share: Trends Analysis Report, 2030.
- Transparency Market Research. (2024). Exosome Isolation Market Size, Share & Research Report, 2034.
- DelveInsight. (2024, October 29). Global Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030.
- Grand View Research. (2024, October). Exosomes Market Size And Share | Industry Report, 2030.
Get Douglas Mulhall’s Book
- About the author: Douglas Mulhall’s latest book, Discovering the Nature of Longevity: Restoring the Heart and Body by Targeting Hidden Stress, explores prevention and therapies for heavy metals contamination. The American Institute of Stress recommends it and carries a Foreword by the Chief author of the American Heart Association statement on toxic heavy metals. He co-develops award-winning certifications and standards for products globally and is a registered ISO expert on a global standard for declaring the contents of products.
- Read more from VIP Executive Contributor Douglas Mulhall